Innate Pharma Cash Flow Conversion Efficiency
Innate Pharma cash flow conversion efficiency. Based on the latest financial reports, Innate Pharma (IPH) has a cash flow conversion efficiency ratio of 0.995x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-21.59 Million ≈ $-25.24 Million USD) by net assets (€-21.70 Million ≈ $-25.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Innate Pharma (2005–2025)
Cash flow conversion efficiency of Innate Pharma from 2005 to 2025. This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IPH stock price for real-time trading data and today's change.
Innate Pharma Cash Flow Conversion Ratio Explained
Innate Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency. Also see Innate Pharma (IPH) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cashbil
JSE:CSB
|
0.225x |
|
Young Poong Precision Corporation
KQ:036560
|
0.021x |
|
Apollo Food Holdings Bhd
KLSE:6432
|
0.007x |
|
STCube Inc
KQ:052020
|
-0.065x |
|
RheinLand Holding AG
DU:RLV
|
N/A |
|
Atakey Patates Gida Sanayi ve Ticaret A.S.
IS:ATAKP
|
0.049x |
|
Bank Ganesha Tbk PT
JK:BGTG
|
0.013x |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
0.119x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2025)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2025. Review Innate Pharma (IPH) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-21.70 Million ≈ $-25.37 Million |
€-52.76 Million ≈ $-61.68 Million |
2.431x | +411.38% |
| 2024-12-31 | €8.83 Million ≈ $10.33 Million |
€-6.90 Million ≈ $-8.06 Million |
-0.781x | -24.44% |
| 2023-12-31 | €51.90 Million ≈ $60.68 Million |
€-32.56 Million ≈ $-38.06 Million |
-0.627x | -77.35% |
| 2022-12-31 | €54.15 Million ≈ $63.31 Million |
€-19.15 Million ≈ $-22.39 Million |
-0.354x | +34.99% |
| 2021-12-31 | €107.44 Million ≈ $125.61 Million |
€-58.46 Million ≈ $-68.34 Million |
-0.544x | -63.81% |
| 2020-12-31 | €155.97 Million ≈ $182.35 Million |
€-51.81 Million ≈ $-60.57 Million |
-0.332x | -306.78% |
| 2019-12-31 | €217.42 Million ≈ $254.18 Million |
€34.92 Million ≈ $40.83 Million |
0.161x | +182.58% |
| 2018-12-31 | €167.24 Million ≈ $195.52 Million |
€-32.53 Million ≈ $-38.03 Million |
-0.195x | +65.21% |
| 2017-12-31 | €85.96 Million ≈ $100.49 Million |
€-48.06 Million ≈ $-56.19 Million |
-0.559x | -30.74% |
| 2016-12-31 | €86.17 Million ≈ $100.74 Million |
€-36.85 Million ≈ $-43.08 Million |
-0.428x | -114.82% |
| 2015-12-31 | €72.07 Million ≈ $84.25 Million |
€207.91 Million ≈ $243.07 Million |
2.885x | +1287.24% |
| 2014-12-31 | €74.63 Million ≈ $87.25 Million |
€-18.13 Million ≈ $-21.20 Million |
-0.243x | +10.74% |
| 2013-12-31 | €40.29 Million ≈ $47.10 Million |
€-10.97 Million ≈ $-12.82 Million |
-0.272x | +39.28% |
| 2012-12-31 | €23.36 Million ≈ $27.31 Million |
€-10.47 Million ≈ $-12.25 Million |
-0.448x | -191.92% |
| 2011-12-31 | €26.62 Million ≈ $31.13 Million |
€12.99 Million ≈ $15.18 Million |
0.488x | +221.55% |
| 2010-12-31 | €33.52 Million ≈ $39.18 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.401x | -218.54% |
| 2009-12-31 | €47.12 Million ≈ $55.09 Million |
€-5.94 Million ≈ $-6.94 Million |
-0.126x | +64.67% |
| 2008-12-31 | €41.34 Million ≈ $48.33 Million |
€-14.74 Million ≈ $-17.23 Million |
-0.357x | -90.56% |
| 2007-12-31 | €49.61 Million ≈ $57.99 Million |
€-9.28 Million ≈ $-10.85 Million |
-0.187x | -3029.85% |
| 2006-12-31 | €56.37 Million ≈ $65.90 Million |
€360.00K ≈ $420.88K |
0.006x | +101.77% |
| 2005-12-31 | €20.07 Million ≈ $23.46 Million |
€-7.25 Million ≈ $-8.47 Million |
-0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more